Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma clinical trial (NCT07257510). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available for mantle cell lymphoma?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma clinical trial (NCT07257510). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma clinical trial (NCT07257510). Contact the study team or your healthcare provider for specific answers.

Question 4

What side effects should I expect from the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma clinical trial (NCT07257510). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma clinical trial (NCT07257510). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I do not achieve minimal residual disease negativity after the six cycles?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma clinical trial (NCT07257510). Contact the study team or your healthcare provider for specific answers.

What this study is about